Breaking News

Over a quarter ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Poxel initiated with an Outperform at JMP Securities » 06:24
06/23/20
06/23
06:24
06/23/20
06:24
PXXLF

Poxel

$0.00 /

+ (+0.00%)

JMP Securities analyst…

JMP Securities analyst Jason Butler initiated coverage of Poxel with an Outperform rating and EUR 21 price target. The analyst cites the company's "most advanced program", imeglimin for type 2 diabetes, having completed its pivotal program in Japan, with Phase 3 trials being planned to begin in the U.S. and Europe. Butler adds that Poxel's two candidates for NASH - PXL770 and PXL650 - also represent "differentiated and compelling opportunities", anticipating their clinical readouts this year to generate "significant near-term value drivers".

ShowHide Related Items >><<
PXXLF Poxel
$0.00 /

+ (+0.00%)

06/23/20 JMP Securities
Poxel initiated with an Outperform at JMP Securities
Initiation
Poxel initiated with an Outperform at JMP Securities » 05:35
06/23/20
06/23
05:35
06/23/20
05:35
PXXLF

Poxel

$0.00 /

+ (+0.00%)

JMP Securities initiated…

JMP Securities initiated coverage of Poxel with an Outperform rating and EUR 21 price target.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.